FPC
XENE icon

Falcon Point Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Falcon Point Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,286
Closed -$128K – 92
2020
Q1 		$128K Sell
11,286
-1,694
-13% -$24.1K 0.28% 88
2019
Q4 		$170K Hold
12,980
– – 0.22% 103
2019
Q3 		$111K Sell
12,980
-12,628
-49% -$119K 0.06% 105
2019
Q2 		$252K Buy
+25,608
New +$245K 0.14% 83

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Falcon Point Capital's XENE Position: Q2 2020 in Review

Falcon Point Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2020, closing a stake of 11,286 shares — an estimated $128K sold.

Falcon Point Capital first reported a position in XENE in Q2 2019 and held it in 4 quarters. The position peaked at $252K in Q2 2019. 79 funds tracked by Wall St. Rank hold XENE as of Q2 2020.

  • Falcon Point Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Falcon Point Capital sold 11,286 Xenon Pharmaceuticals shares in Q2 2020, an estimated $128K.
  • Falcon Point Capital first reported a position in Xenon Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Falcon Point Capital's Xenon Pharmaceuticals position peaked at $252K in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2020.

Based on Falcon Point Capital's 13F filing for Q2 2020, filed 21 Jul 2020.